Poolbeg Pharma has a unique biomarker platform in development which may be used to identify those at risk of developing severe disease.
Human challenge trials were conducted with front loaded sample collection time points to interrogate the earliest signs of disease following infection. Poolbeg Pharma has identified a set of biomarkers that can predict the severity of disease a patient will suffer before the onset of symptoms.
Current antiviral treatments can be given prophylactically to at-risk populations exposed to an infected individual. These treatments can cause adverse effects and are often layered on top of existing medications in these treatment groups.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.